MARKET

TMBR

TMBR

Timber Pharmaceuticals
AMEX

Real-time Quotes | Nasdaq Last Sale

1.080
-0.040
-3.57%
Opening 12:13 05/17 EDT
OPEN
1.100
PREV CLOSE
1.120
HIGH
1.130
LOW
1.080
VOLUME
327.32K
TURNOVER
--
52 WEEK HIGH
6.30
52 WEEK LOW
0.6651
MARKET CAP
39.79M
P/E (TTM)
-0.6998
1D
5D
1M
3M
1Y
5Y
Timber Pharmaceuticals Q1 EPS $(0.05) Up From $(0.56) YoY, Sales $40.73K Up From $26.91K YoY
Timber Pharmaceuticals (AMEX:TMBR) reported quarterly losses of $(0.05) per share. This is a 91.07 percent increase over losses of $(0.56) per share from the same period last year. The company reported $40.73 thousand
Benzinga · 5d ago
Timber Pharmaceuticals reports Q1 results
Timber Pharmaceuticals (TMBR): Q1 GAAP EPS of -$0.05.Revenue of $40.7K (+51.3% Y/Y)Press Release
Seekingalpha · 5d ago
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2021 Financial Results
BASKING RIDGE, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and ...
GlobeNewswire · 5d ago
10-Q: TIMBER PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- Management's Discussion and Analysis of the Results of Operations The following discussion and analysis of our financial...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
Timber Pharmaceuticals Narrows Q1 Net Loss to $0.05 Per Share
MT Newswires · 5d ago
Timber Pharmaceuticals Files for Up to $100 Million Mixed Shelf
MT Newswires · 05/05 03:20
BRIEF-Timber Pharmaceuticals Inc Files For Mixed Shelf Of Up To $100 Mln
reuters.com · 05/04 13:26
BRIEF-Timber Pharmaceuticals Inc Files For Resale Of 7.8 Mln Shares Of Common Stock By The Selling Stockholders
reuters.com · 05/04 13:24
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TMBR. Analyze the recent business situations of Timber Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TMBR stock price target is 2.250 with a high estimate of 2.250 and a low estimate of 2.250.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 880.79K
% Owned: 2.39%
Shares Outstanding: 36.84M
TypeInstitutionsShares
Increased
5
172.81K
New
5
78.64K
Decreased
5
557.09K
Sold Out
7
10.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.19%
Pharmaceuticals & Medical Research
+0.56%
Key Executives
Chief Executive Officer/Director
John Koconis
Chief Financial Officer/Executive Vice President
Joseph Lucchese
Chief Operating Officer/Executive Vice President/Secretary/Director
Zachary Rome
Chief Accounting Officer
Joyce Goto
Other
Alan Mendelsohn
Director
Gianluca Pirozzi
Director
Edward Sitar
Independent Director
David Cohen
Independent Director
Lubor Gaal
No Data
About TMBR
Timber Pharmaceuticals, Inc., formerly BioPharmX Corporation, is a biopharmaceutical company. The Company is focused on the development and commercialization of treatments for orphan dermatologic diseases. It is developing treatments for rare dermatologic diseases including congenital ichthyosis (CI), tuberous sclerosis complex (TSC), and localized scleroderma. Its pipeline includes TMB-001, TMB-002 and TMB-003. TMB-001 is a topical isotretinoin, which is being developed for the treatment of moderate to severe subtypes of CI. TMB-002, a topical rapamycin, is being developed for the treatment of facial angiofibromas (FAs) in TSC. TMB-003 is a topical / subcutaneous ET-A receptor antagonist, which is being developed for localized scleroderma.

Webull offers kinds of Timber Pharmaceuticals Inc stock information, including AMEX:TMBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TMBR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TMBR stock methods without spending real money on the virtual paper trading platform.